REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical Co Ltd
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser:
Société Générale S.A.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical CO LTD
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
20/07/2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES: Shire PLC
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
2,425,739
0.31
6,951,080
0.89
(2) Cash-settled derivatives:
4,126,997
0.53
5,026
0.00
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
121,500
0.02
0
0.00
TOTAL:
6,674,236
0.85
6,956,106
0.89
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
JPY
Ordinary
Purchase
4,700
4728
Ordinary
Purchase
2,500
4728
Ordinary
Purchase
200
4748
Ordinary
Purchase
200
4709
Ordinary
Purchase
200
4731
Ordinary
Purchase
200
4703
Ordinary
Purchase
200
4709
Ordinary
Purchase
100
4705
Ordinary
Purchase
100
4736
Ordinary
Purchase
100
4705
Ordinary
Purchase
200
4749
Ordinary
Purchase
12,900
4728
Ordinary
Purchase
600
4700
Ordinary
Purchase
400
4706
Ordinary
Purchase
100
4706
Ordinary
Purchase
300
4746
Ordinary
Purchase
600
4759
Ordinary
Purchase
500
4757
Ordinary
Purchase
100
4749
Ordinary
Purchase
500
4750
Ordinary
Purchase
700
4695
Ordinary
Purchase
200
4747
Ordinary
Purchase
600
4748
Ordinary
Purchase
1,000
4719
Ordinary
Purchase
100
4709
Ordinary
Purchase
100
4749
Ordinary
Purchase
300
4750
Ordinary
Purchase
100
4749
Ordinary
Purchase
1,000
4753
Ordinary
Purchase
200
4757
Ordinary
Purchase
100
4744
Ordinary
Purchase
200
4751
Ordinary
Purchase
100
4749
Ordinary
Purchase
100
4750
Ordinary
Purchase
100
4749
Ordinary
Purchase
400
4749
Ordinary
Purchase
100
4756
Ordinary
Purchase
500
4757
Ordinary
Purchase
300
4699
Ordinary
Purchase
100
4701
Ordinary
Purchase
1,000
4750
Ordinary
Purchase
100
4700
Ordinary
Purchase
1,000
4694
Ordinary
Purchase
200
4706
Ordinary
Purchase
100
4706
Ordinary
Purchase
300
4705
Ordinary
Purchase
500
4728
Ordinary
Purchase
700
4753
Ordinary
Purchase
1,100
4730
Ordinary
Purchase
100
4733
Ordinary
Purchase
100
4762
Ordinary
Purchase
200
4749
Ordinary
Purchase
500
4755
Ordinary
Purchase
2,000
4706
Ordinary
Purchase
200
4755
Ordinary
Purchase
800
4756
Ordinary
Purchase
1,500
4748
Ordinary
Purchase
200
4759
Ordinary
Purchase
600
4750
Ordinary
Purchase
500
4756
Ordinary
Purchase
700
4698
Ordinary
Purchase
500
4756
Ordinary
Purchase
100
4705
Ordinary
Purchase
200
4706
Ordinary
Purchase
400
4747
Ordinary
Purchase
100
4759
Ordinary
Purchase
600
4751
Ordinary
Purchase
500
4748
Ordinary
Purchase
500
4748
Ordinary
Purchase
200
4700
Ordinary
Purchase
100
4750
Ordinary
Purchase
1,200
4743
Ordinary
Purchase
1,600
4728
Ordinary
Purchase
600
4750
Ordinary
Purchase
300
4707
Ordinary
Purchase
300
4749
Ordinary
Purchase
130
4734
Ordinary
Purchase
75
4727
Ordinary
Purchase
100
4759
Ordinary
Sale
200
4723
Ordinary
Sale
200
4706
Ordinary
Sale
500
4738
Ordinary
Sale
1,000
4696
Ordinary
Sale
100
4730
Ordinary
Sale
400
4704
Ordinary
Sale
100
4733
Ordinary
Sale
100
4730
Ordinary
Sale
100
4730
Ordinary
Sale
300
4701
Ordinary
Sale
200
4706
Ordinary
Sale
800
4745
Ordinary
Sale
500
4748
Ordinary
Sale
100
4733
Ordinary
Sale
100
4756
Ordinary
Sale
100
4736
Ordinary
Sale
100
4735
Ordinary
Sale
200
4704
Ordinary
Sale
800
4737
Ordinary
Sale
600
4715
Ordinary
Sale
1,000
4729
Ordinary
Sale
300
4730
Ordinary
Sale
100
4739
Ordinary
Sale
800
4699
Ordinary
Sale
1,000
4734
Ordinary
Sale
400
4711
Ordinary
Sale
700
4753
Ordinary
Sale
100
4737
Ordinary
Sale
100
4711
Ordinary
Sale
300
4709
Ordinary
Sale
300
4698
Ordinary
Sale
1,000
4728
Ordinary
Sale
1,900
4759
Ordinary
Sale
100
4698
Ordinary
Sale
600
4759
Ordinary
Sale
300
4710
Ordinary
Sale
100
4710
Ordinary
Sale
200
4751
Ordinary
Sale
1,300
4750
Ordinary
Sale
1,300
4751
Ordinary
Sale
300
4709
Ordinary
Sale
200
4705
Ordinary
Sale
2,000
4704
Ordinary
Sale
1,000
4697
Ordinary
Sale
300
4707
Ordinary
Sale
200
4709
Ordinary
Sale
600
4706
Ordinary
Sale
100
4707
Ordinary
Sale
300
4708
Ordinary
Sale
200
4755
Ordinary
Sale
1,500
4705
Ordinary
Sale
100
4703
Ordinary
Sale
100
4697
Ordinary
Sale
800
4746
Ordinary
Sale
500
4745
Ordinary
Sale
100
4708
Ordinary
Sale
500
4757
Ordinary
Sale
500
4731
Ordinary
Sale
600
4704
Ordinary
Sale
200
4751
Ordinary
Sale
200
4697
Ordinary
Sale
400
4749
Ordinary
Sale
200
4736
Ordinary
Sale
300
4756
Ordinary
Sale
1,200
4746
Ordinary
Sale
700
4707
Ordinary
Sale
700
4696
Ordinary
Sale
400
4755
Ordinary
Sale
300
4706
Ordinary
Sale
300
4701
Ordinary
Sale
300
4735
Ordinary
Sale
300
4704
Ordinary
Sale
100
4704
Ordinary
Sale
100
4706
Ordinary
Sale
100
4732
Ordinary
Sale
100
4710
Ordinary
Sale
100
4698
Ordinary
Sale
20,975
4728.5447
Ordinary
Sale
80
4725
Ordinary
Sale
100
4759
Ordinary
Sale
100
4759
Total Purchases
50,905
Total Sales
55,555
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit JPY
Ordinary
CFD
Increasing a long position
20,975
4728.5447
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit JPY
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit JPY
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable) JPY
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
YES
Date of disclosure:
23/07/2018
Contact name:
Olivier Vero
Telephone number:
+44 20 7676 6969
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
1. KEY INFORMATION
Full name of person making disclosure:
SOCIETE GENERALE SA
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:
Takeda Pharmaceutical CO LTD
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security
Product description e.g. call option
Written or purchased
Number of securities to which option or derivative relates
Exercise price per unit
Type
Expiry date
JPY
e.g. American, European etc.
Ordinary
OTC put-option
Sale
15,700
4707
European options
14/12/2018
Ordinary
OTC put-option
Sale
30,000
5075.10
European options
14/12/2018
Ordinary
OTC put-option
Sale
29,600
5073.65
European options
14/12/2018
Ordinary
OTC put-option
Sale
15,500
4491.40
European options
14/12/2018
Ordinary
OTC put-option
Sale
30,700
4533.90
European options
14/12/2018
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRETPGUQGMUPRURW
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement